Acellular compositions for treating inflammatory disorders
View Patent ↗Acellular compositions for treating inflammation, comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. Components of the acellular compositions may be derived from biologic materials, such as blood clots and urine. Components may also be obtained from cell cultures.
1. A substantially acellular anti-inflammatory cytokine composition comprising:
interleukin-1 receptor antagonist (IL-1ra);
soluble tumor necrosis factor receptor I (sTNF-RI);
soluble tumor necrosis factor receptor II (sTNF-RII); and
at least one growth factor selected from epidermal growth factor (EGF), hepatocyte growth factor (HGF), and platelet-derived growth factor BB (PDGF-BB);
wherein at least one of the IL-1ra, sTNF-RI, sTNF-RII and the selected growth factor is isolated from urine, clotted blood, or tissue culture, the at least one growth factor having a concentration greater than the concentration of the at least one growth factor in normal blood, and wherein the composition is substantially free of viable cells.
2. The anti-inflammatory composition according to claim 1 , wherein the IL1ra has a concentration of at least about 10,000 pg/ml, and the sTNF-RI has a concentration of at least about 1,200 pg/ml.
3. The anti-inflammatory composition according to claim 1 , wherein the selected growth factor is epidermal growth factor and has a concentration of at least about 800 pg/ml.
4. The anti-inflammatory composition according to claim 1 , further comprising soluble interleukin-1 receptor II (sIL-1RII).
5. The anti-inflammatory composition according to claim 1 , wherein the growth factor has a concentration of at least about 3000 pg/ml.
6. The anti-inflammatory composition according to claim 1 , wherein the anti-inflammatory cytokine composition is freeze dried such that the composition is substantially free of viable cells.
7. The anti-inflammatory composition according to claim 1 , wherein the interleukin-1 receptor antagonist is derived from urine.
8. The anti-inflammatory composition according to claim 1 , wherein the interleukin-1 receptor antagonist is derived from tissue culture.
9. The anti-inflammatory composition according to claim 1 , wherein the interleukin-1 antagonist is derived from a blood clot.
10. The anti-inflammatory composition according to claim 1 , further comprising a carrier material selected from hyaluronic acid, collagen or a mixture thereof.
11. A substantially acellular composition for the treatment of a disorder mediated by interleukin-1 (IL-1) comprising:
at least about 25,000 pg/ml interleukin-1 receptor antagonist (IL-1ra);
at least about 2,500 pg/ml soluble tumor necrosis factor receptor II (sTNF-RII); and
a protein selected from epidermal growth factor, hepatocyte growth factor, and platelet-derived growth factor BB, wherein the concentration of the selected protein in the composition is greater than the concentration of the selected protein in normal blood;
wherein the composition is substantially acellular.
12. The composition according to claim 11 , wherein at least one of IL-1ra, sTNF-RII, and the selected protein is isolated from urine, clotted blood, or tissue culture.
13. The composition according to claim 11 , wherein at least one of IL-1ra, sTNF-RII, and the selected protein is obtained from culture medium from a monolayer cell culture, a bioreactor, or a non-adherent cell culture.
14. The composition according to claim 11 , further comprising soluble interleukin-1 receptor II (sIL-1RII).
15. The composition according to claim 11 , wherein the composition is freeze dried such that the composition is substantially free of viable cells.
16. The composition according to claim 11 , wherein the selected protein is epidermal growth factor and has a concentration of at least about 800 pg/ml.
17. The composition according to claim 11 , further comprising hyaluronic acid, collagen, or a mixture thereof.
18. A anti-inflammatory composition comprising:
soluble tumor necrosis factor receptor II (sTNF-RII); and
at least one growth factor selected from epidermal growth factor (EGF), hepatocyte growth factor (HGF), and platelet-derived growth factor BB (PDGF-BB), the at least one growth factor have a concentration greater than the concentration of the at least one growth factor in normal blood;
wherein at least one of the sTNF-RII and the selected growth factor is isolated from urine, clotted blood, or tissue culture and the composition is substantially free of viable cells.
19. The composition of claim 18 , wherein the sTNF-RII has a concentration of at least about 2,500 pg/ml.
20. The composition according to claim 18 , wherein the sTNF-RII has a concentration of at least three times the concentration of sTNF-RII in normal blood.
21. The composition of claim 18 , wherein the selected growth factor is epidermal growth factor and has a concentration of at least about 800 pg/ml.
22. The composition of claim 18 , wherein the selected growth factor has a concentration at least about twice the concentration of the selected growth factor in normal blood.
23. The composition according to claim 18 , further comprising interleukin-1 receptor antagonist at a concentration of at least about 10,000 pg/ml.
24. The composition according to claim 18 , further comprising soluble tumor necrosis factor receptor I (sTNF-RI) at a concentration of at least about 1,200 pg/ml.
25. The composition according to claim 18 , further comprising soluble interleukin-1 receptor II (sIL-1RII).
26. The composition according to claim 25 , wherein the sIL-1RII has a concentration at least about twice the concentration of sIL-1RII in normal blood.
27. The composition according to claim 18 , further comprising a carrier material selected from hyaluronic acid, collagen or a mixture thereof.
28. The composition according to claim 18 , wherein the composition is freeze dried such that the composition is substantially free of viable cells.